{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:47:04Z","timestamp":1761101224097},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s13277-014-1635-4","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T06:49:08Z","timestamp":1393310948000},"page":"4841-4848","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"35","author":[{"given":"Xuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"issue":"Suppl 2","key":"1635_CR1","doi-asserted-by":"crossref","first-page":"i191","DOI":"10.1093\/annonc\/mdi719","volume":"16","author":"G Mariani","year":"2005","unstructured":"Mariani G. New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol. 2005;16 Suppl 2:i191\u20134.","journal-title":"Ann Oncol"},{"key":"1635_CR2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/jnci\/84.24.1875","volume":"84","author":"N Weidner","year":"1992","unstructured":"Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"1635_CR3","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/0008-5472.CAN-03-1957","volume":"64","author":"B Uzzan","year":"2004","unstructured":"Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004;64:2941\u201355.","journal-title":"Cancer Res"},{"key":"1635_CR4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0002-9440(10)65713-6","volume":"153","author":"SW McLeskey","year":"1998","unstructured":"McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol. 1998;153:1993\u20132006.","journal-title":"Am J Pathol"},{"key":"1635_CR5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2000.18.7.1423","volume":"18","author":"B Linderholm","year":"2000","unstructured":"Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol. 2000;18:1423\u201331.","journal-title":"J Clin Oncol"},{"key":"1635_CR6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ejca.2008.01.005","volume":"44","author":"M Marty","year":"2008","unstructured":"Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44:912\u201320.","journal-title":"Eur J Cancer"},{"key":"1635_CR7","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593\u20139.","journal-title":"Cancer Res"},{"key":"1635_CR8","first-page":"1843","volume":"2","author":"D Belotti","year":"1996","unstructured":"Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843\u20139.","journal-title":"Clin Cancer Res"},{"key":"1635_CR9","first-page":"3369","volume":"61","author":"CJ Sweeney","year":"2001","unstructured":"Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369\u201372.","journal-title":"Cancer Res"},{"key":"1635_CR10","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"X Pivot","year":"2009","unstructured":"Pivot X, Verma S, Thomssen C, Passos-Coelho JL, Latini L, Ciruelos E, et al. Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or metastatic breast cancer. J Clin Oncol. 2009;27:15s. abstr 1094.","journal-title":"J Clin Oncol"},{"key":"1635_CR11","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"NJ Robert","year":"2009","unstructured":"Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent. J Clin Oncol. 2009;27:15S. abstr1005.","journal-title":"J Clin Oncol"},{"key":"1635_CR12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"1635_CR13","unstructured":"Higgins J, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. Oxford: The Cochrane Collaboration 2009; www.cochrane-handbook.org . Accessed 20 May 2010."},{"key":"1635_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1635_CR15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1635_CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(12)70566-1","volume":"14","author":"I Lang","year":"2013","unstructured":"Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for her2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013;14:125\u201333.","journal-title":"Lancet Oncol"},{"key":"1635_CR17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1470-2045(11)70037-7","volume":"12","author":"M Martin","year":"2011","unstructured":"Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2011;12:369\u201376.","journal-title":"Lancet Oncol"},{"key":"1635_CR18","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","volume":"27","author":"R Gray","year":"2009","unstructured":"Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of e2100: a phase iii trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966\u201372.","journal-title":"J Clin Oncol"},{"key":"1635_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clbc.2011.03.019","volume":"11","author":"A Brufsky","year":"2011","unstructured":"Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Cancer. 2011;11:211\u201320.","journal-title":"Clin Breast Cancer"},{"key":"1635_CR20","unstructured":"Genentech, Inc. US Prescribing Information for Avastin.2009; http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125085s0168lbl.pdf . Accessed 11 Mar 2010."},{"key":"1635_CR21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-013-2552-8","volume":"139","author":"HS Rugo","year":"2013","unstructured":"Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, et al. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013;139:411\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"1635_CR22","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666\u201376.","journal-title":"N Engl J Med"},{"key":"1635_CR23","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. Ribbon-1: randomized, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252\u201360.","journal-title":"J Clin Oncol"},{"key":"1635_CR24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10637-009-9310-0","volume":"29","author":"JB Lee","year":"2011","unstructured":"Lee JB, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs. 2011;29:182\u20138.","journal-title":"Invest New Drugs"},{"key":"1635_CR25","doi-asserted-by":"crossref","unstructured":"Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M: Bevacizumab and breast cancer: a meta-analysis of first-line phase iii studies and a critical reappraisal of available evidence. J Oncol 2012;2012:417673.","DOI":"10.1155\/2012\/417673"},{"key":"1635_CR26","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","volume":"24","author":"DW Miles","year":"2013","unstructured":"Miles DW, Dieras V, Cortes J, Duenne AA, Yi J, O\u2019Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013;24:2773\u201380.","journal-title":"Ann Oncol"},{"key":"1635_CR27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0140-6736(93)93004-K","volume":"341","author":"LA Stewart","year":"1993","unstructured":"Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993;341:418\u201322.","journal-title":"Lancet"},{"key":"1635_CR28","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ejca.2008.12.016","volume":"45","author":"KJ Dedes","year":"2009","unstructured":"Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45:1397\u2013406.","journal-title":"Eur J Cancer"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1635-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-1635-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1635-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T23:15:09Z","timestamp":1565219709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-1635-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-1635-4","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,26]]}}}